Company Analysis
Sign in

4D Molecular Therapeutics, Inc. (FDMT)

Nasdaq: FDMT · Biological Products, (No Diagnostic Substances) · Emeryville, CA · filing with the SEC since 2015
Full chart Alerts Compare
Grade6.4
◀ Past 5.8● Present 7.1▶ Future 6.2
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

15 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to 4D Molecular Therapeutics, Inc.’s names, not what it holds today.

Patents granted
15
15 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against none in 2024 and 5 in 2023
Applications published
31
2 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals12
Biotechnology3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
4D MOLECULAR THERAPEUTICS INC. its own name
US, as the owner printed on each patent
15 granted
30 published
4D MOLECULAR THERAPEUTICS INC. its own name
named as the applicant on its applications, in US
0 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 12, 202311,840,704Adeno-associated virus variant capsids and methods of use thereofPharmaceuticals4D MOLECULAR THERAPEUTICS INC.
Nov 7, 202311,807,868Adeno-associated variants, formulations and methods for pulmonary deliveryBiotechnology4D MOLECULAR THERAPEUTICS INC.
Sep 26, 202311,766,489Adeno-associated virus variant capsids and use for inhibiting angiogenesisBiotechnology4D MOLECULAR THERAPEUTICS INC.
Sep 26, 202311,766,487Treatments for retinal diseasePharmaceuticals4D MOLECULAR THERAPEUTICS INC.
Feb 14, 202311,576,983Treatments for retinal diseasePharmaceuticals4D MOLECULAR THERAPEUTICS INC.
Dec 13, 202211,524,081Codon optimized REP1 genes and uses thereofPharmaceuticals4D MOLECULAR THERAPEUTICS INC.
Nov 15, 202211,499,166Adeno-associated variants, formulations and methods for pulmonary deliveryBiotechnology4D MOLECULAR THERAPEUTICS INC.
Aug 23, 202211,419,949Adeno-associated virus variant capsids and methods of use thereofPharmaceuticals4D MOLECULAR THERAPEUTICS INC.
Jun 21, 202211,364,308Adeno-associated virus variant capsids and methods of use thereofPharmaceuticals4D MOLECULAR THERAPEUTICS INC.
Jun 14, 202211,357,870Codon optimized REP1 genes and uses thereofPharmaceuticals4D MOLECULAR THERAPEUTICS INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
May 22, 20252025/0163469ADENO-ASSOCIATED VIRUS VARIANT CAPSIDS AND METHODS OF USE THEREOFPharmaceuticals4D MOLECULAR THERAPEUTICS INC.
Feb 20, 20252025/0057987Compositions and Methods for Treatment of Ocular Disease Associated with AngiogenesisBiotechnology4D MOLECULAR THERAPEUTICS INC.
Oct 31, 20242024/0358859CODON OPTIMIZED REP1 GENES AND USES THEREOFPharmaceuticals4D MOLECULAR THERAPEUTICS INC.
Oct 10, 20242024/0335560ADENO-ASSOCIATED VIRUS VARIANT CAPSIDS AND USE FOR INHIBITING ANGIOGENESISBiotechnology4D MOLECULAR THERAPEUTICS INC.
Jul 11, 20242024/0226336Compositions and Methods for Treatment of Ocular Disease Associated with AngiogenesisBiotechnology4D MOLECULAR THERAPEUTICS INC.
Apr 25, 20242024/0131195Compositions and Methods for Treatment of Ocular Disease Associated with AngiogenesisBiotechnology4D MOLECULAR THERAPEUTICS INC.
Feb 29, 20242024/0067987ADENO-ASSOCIATED VARIANTS, FORMULATIONS AND METHODS FOR PULMONARY DELIVERYBiotechnology4D MOLECULAR THERAPEUTICS INC.
Feb 29, 20242024/0066145ADENO-ASSOCIATED VIRUS VARIANT CAPSIDS WITH IMPROVED RETINAL TRANSDUCTION AND USES THEREOFPharmaceuticals4D MOLECULAR THERAPEUTICS INC.
Jan 18, 20242024/0018498CODON OPTIMIZED GLA GENES AND USES THEREOFPharmaceuticals4D MOLECULAR THERAPEUTICS INC.
Oct 26, 20232023/0340042CODON OPTIMIZED RPGRORF15 GENES AND USES THEREOFPharmaceuticals4D MOLECULAR THERAPEUTICS INC.
What it applied for, 2024 to 2025: Biotechnology 5 · Pharmaceuticals 4.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton FDMT · research, not advice